Lamassu BioTech

Science-Driven, Innovative Solutions to Meet Patient Needs: At Lamassu, our team of dedicated physicians, engineers, and translational scientists, are driven by a passion to treat patients like family. Our goal is to speed the innovation process by bringing transformational treatments from concept to bedside faster than other companies. Lamassu’s patient-centric approach to research focuses on making advancements that address unmet needs with novel and targeted strategies, ensuring greater efficiency and shorter approval timeframes. Learn more at www.LamassuBiotech.com.

The approval of a new medical treatment can take, on average, over 10 years, according to most industry experts. While the process of providing new drugs to be a safe and effective treatment is a vital procedure, the Lamassu Method aims to leverage innovative and collaborative approaches to go from lab to bedside faster. That’s how we accelerate hope and healing. Learn more at LamassuBiotech.com.

The Lamassu Method: Lamassu leverages innovative approaches to drive collaboration between academia and industry through translational research. Our model is to identify novel therapeutics with high potential for clinical impact, having strong scientific rationale and preclinical efficacy data. Lamassu builds the best scientific case, examining the mechanism, exploring additional models and indications, and identifying the most promising path forward for regulatory approval and clinical impact. We capitalize on our expertise in early translational research to bring products to Phase I/II and partner with clinical and commercial development specialists to advance clinical trials through the approval pipeline. Learn more at www.LamassuBiotech.com.

#ThrowbackThursday “Reducing the risks associated with biotech innovation also requires stronger public-private partnerships that share the financial burden of early-stage research. Government grants, tax incentives, and other forms of support can help de-risk drug development, encouraging the private sector to invest in new therapies for otherwise unaddressed ailments. Lamassu BioTech’s SA53 and RABI-767, experimental treatments are a model in this regard, being developed with domestic and international partners as well as the Mayo Clinic and Cleveland Clinic. These efforts to address unmet needs for cancer and pancreatitis respectively have advanced, in part, thanks to support from federal funding from the The National Institutes of Health.” Read Dr. Gabi Hanna MD.’s full op-ed from RealClearHealth here: https://lnkd.in/etH94bu2

Lamassu BioTech is accelerating hope and healing. A private clinical stage company focusing on accelerating treatment, Lamassu’s team of dedicated physicians, researchers, and translational scientists are driven by a passion to treat patients like family. Follow #LamassuBioTech today using @LamassuBioTech on LinkedIn, Facebook, Instagram and Twitter.

𝐌𝐞𝐞𝐭 𝐋𝐚𝐦𝐚𝐬𝐬𝐮 𝐁𝐢𝐨𝐭𝐞𝐜𝐡: Lamassu Biotech’s Sr. Director Clinical Development and Operations Jill Palmenberg has been in clinical research for 28 years, with a primary focus on oncology, as well as experience with pancreatitis, diabetes, Alzheimer's, Giant Axonal Neuropathy, RETT Syndrome, coagulation, and dry eye. Jill has developed a broad skill set having served in a wide range of roles in drug development, including Clinical Supplies, Safety Management, Clinical Monitoring, Clinical Trials Development and Management. At Lamassu, Jill enjoys working as part of a diverse team that fosters a supportive and dynamic work environment. She recently shared, “Each individual brings a unique skill set to the table, allowing us to achieve the work of a much larger team. Managing the development of new treatments and enhancing existing healthcare solutions requires a comprehensive and detailed skill set. With the Lamassu team, we proudly bring research out of the lab and into the lives of vulnerable populations.” Learn more about Lamassu’s team at www.LamassuBiotech.com.

Lamassu BioTech is accelerating hope and healing. A private clinical stage company focusing on accelerating treatment, Lamassu’s team of dedicated physicians, researchers, and translational scientists are driven by a passion to treat patients like family. Follow Lamassu BioTech today using @LamassuBioTech on LinkedIn, Facebook, Instagram and Twitter.

SA53 is bringing new hope to patients with metastatic cancer. Lamassu’s innovative targeted therapy project focuses on advancing SA53, a novel therapeutic that targets p53 wild-type sarcomas, malignant tumors of connective or non-epithelial tissue. SA53 has demonstrated remarkable potency, efficacy and safety in preclinical models, positioning it for an Investigational New Drug (IND) submission. Learn more at www.LamassuBiotech.com.

Lamassu Biotech’s CEO Gabi Hanna MD., recently wrote in a column for RealClearHealth: “Biotechnology, by its nature, is a high-risk industry. Substantial upfront costs paired with low success rates demand a high return to make it a sustainable innovative business model and attract investors in the early stage of development. On average only about one in ten drugs that enter clinical trials ever make it to market. As a result, the few drugs that do succeed must cover their own development costs and subsidize the many that fail, driving prices even higher.” Read the full column via the link below: https://lnkd.in/etH94bu2.

Lamassu Biotech CEO Gabi Hanna MD., pictured here alongside Ambassador Dr. Deborah Brix and Harbinger Health CEO Dr. Steve Hahn, joined business leaders, policy makers, educators and healthcare professionals from around the world at the 2024 NYC C3 DAVOS OF HEALTHCARE™, held in conjunction with the United Nations General Assembly Week. The event offered great dialogue around bolstering and promoting US and Arab initiatives, with a significant focus on a range of healthcare topics including infrastructure, the shift from communicable diseases, the future of primary healthcare, and cooperative assistance for knowledge transfer.